Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shuganhuazhuo Formula in Advanced Hepatocellular Carcinoma
NCT07691645Phase 2Not yet recruiting
- Sponsor
- Xiangqian Biotechnology
- Start
- Sep 2027
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Shuganhuazhuo Formula in hepatocellular carcinoma (HCC) (2 arms), sponsored by Xiangqian Biotechnology. Primary endpoint: Liver reserve function at 6 months. Planned start Sep 2027; status: not yet recruiting.
02
Drugs
Shuganhuazhuo Formula
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07691645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691645.